55,164 Shares in Boston Scientific Corporation $BSX Acquired by Jackson Square Capital LLC

Jackson Square Capital LLC bought a new position in Boston Scientific Corporation (NYSE:BSX) during the third quarter, Holdings Channel.com reports. The fund bought 55,164 shares of the medical equipment provider’s stock, valued at approximately $2,408,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BSX. Clal Insurance Enterprises Holdings Ltd bought a new stake in Boston Scientific during the first quarter worth approximately $28,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Boston Scientific in the first quarter valued at $32,000. Measured Wealth Private Client Group LLC increased its holdings in shares of Boston Scientific by 244.9% in the first quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 387 shares in the last quarter. Kelleher Financial Advisors bought a new position in shares of Boston Scientific in the second quarter valued at $25,000. Finally, Nvwm LLC lifted its position in shares of Boston Scientific by 526.2% during the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 542 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig acquired 5,000 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the transaction, the director owned 30,359 shares of the company’s stock, valued at $1,380,727.32. The trade was a 19.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney bought 186,240 shares of the stock in a transaction on Monday, August 3rd. The shares were acquired at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have acquired 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on BSX shares. Leerink Partners reduced their price objective on Boston Scientific from $60.00 to $55.00 in a research note on Friday, October 9th. Mizuho set a $55.00 target price on Boston Scientific in a report on Tuesday, October 13th. Argus reaffirmed a “hold” rating on shares of Boston Scientific in a research report on Friday, July 31st. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $60.00 target price (down from $75.00) on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Oppenheimer reduced their target price on Boston Scientific from $85.00 to $65.00 and set an “outperform” rating for the company in a report on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $68.23.

Boston Scientific Trading Up 0.7%

NYSE BSX traded up $0.29 on Monday, hitting $44.68. 5,151,036 shares of the stock were exchanged, compared to its average volume of 18,517,102. The company’s 50-day moving average price is $46.06 and its two-hundred day moving average price is $49.67. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 52-week low of $41.38 and a 52-week high of $105.65. The company has a market capitalization of $64.76 billion, a price-to-earnings ratio of 18.08, a P/E/G ratio of 1.07 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts predict that Boston Scientific Corporation will post 3.24 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.